Graphite Bio Inc
NASDAQ:GRPH
Graphite Bio Inc
NASDAQ:GRPH
Price:
50 USD
Market Closed
Updated:
May 9, 2024
P/E
Price to Earnings
Price to Earnings
-23.3
Current
-12.9
Median
26.8
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-23.3
Market Cap
/
2.9B
Net Income
-124.7m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Graphite Bio Inc
NASDAQ:GRPH
|
2.9B USD | -23.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 58.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.3B USD | 44.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 29.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.8B USD | 27.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.8B AUD | 35.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.5B USD | 166.4 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
47.3B USD | -7.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.4B USD | 27.8 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 73.4 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-125
2-Years Forward
P/E
-125
3-Years Forward
P/E
N/A
You don't have any saved screeners yet
